We are thrilled to announce that we started in July 2024 the id.DRIVE surveillance study in Europe. The surveillance study is a multi-country hospital-based study which monitors viral respiratory infections in adults hospitalised for severe acute respiratory infection (SARI).
This sentinel study is a common data collection which builds the foundation for a sustainable study-ready system that can be activated to evaluate effectiveness of vaccines and related pharmaceutical products. The COVID-19 Vaccine Effectiveness (CVE) study is ongoing since 2021, and a a respiratory syncytial virus (RSV) vaccine effectiveness study will be launched later in 2024. The protocols for the vaccines effectiveness and surveillance studies can be found here: https://iddrive.eu/study-documents/.
The first site to start recruitment for the common data collection is Universitätsklinikum Frankfurt, on Friday 26 July 2024. Activation of the other sites in Italy, Germany and Spain will continue during the summer. These sites will transition from recruiting solely for the CVE study to the common data collection. New sites are being setup for the common data collection in France and UK as well as additional sites in Spain. More info on study contributors: https://iddrive.eu/study-contributors/